TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1453750

Group type: EXPERIMENTAL
Intervention: D860 plus Tong Yu Ling (TYL)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Tong Yu Ling (TYL) alone
Number of subjects: 72

Group type: COMPARATOR
Intervention: D860 alone
Number of subjects: 72
Study: 6085386

Group type: EXPERIMENTAL
Intervention: 5‐mg nitrendipine tablet
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 10‐mg nitrendipine tablet
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 20‐mg nitrendipine tablet
Number of subjects: 22

Group type: COMPARATOR
Intervention: Liquid suspension of nitrendipine
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: All doses (5‐mg, 10‐mg, 20‐mg)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Nitrendipine and its metabolites
Number of subjects: 22
Study: 31215773

Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Risedronate
Number of subjects: 0
Study: 30046610

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) at ST36-ST37, 20 minutes twice a day for five days
Number of subjects: 71

Group type: COMPARATOR
Intervention: Conventional therapies including fluid resuscitation, anti‐infection, vasoactive agents, mechanical ventilation, supply of enteral nutrition, and glutamine
Number of subjects: 71
Study: 27479098

Group type: EXPERIMENTAL
Intervention: Complicated Grief Treatment (CGT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Supportive Counseling (SC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Complicated Grief Treatment (CGT) with a supportive person
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Complicated Grief Treatment (CGT) without a supportive person
Number of subjects: 0
Study: 25269885

Group type: EXPERIMENTAL
Intervention: Saxagliptin/metformin XR 5/500 mg FDC tablet
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Saxagliptin/metformin XR 5/1,000 mg FDC tablet
Number of subjects: 64

Group type: COMPARATOR
Intervention: Co-administration of saxagliptin and metformin XR
Number of subjects: 64
Study: 22257600

Group type: EXPERIMENTAL
Intervention: Assisted BLS (with software assistance)
Number of subjects: 141
Study: 20195158

Group type: EXPERIMENTAL
Intervention: Slow-release melatonin (6 mg) given at bedtime for 4 weeks
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 18343246

Group type: EXPERIMENTAL
Intervention: Doxazosin GITS 4 mg (titrated to 8 mg if needed)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Atenolol 50 mg (titrated to 100 mg if needed)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Doxazosin GITS
Number of subjects: 60

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Doxazosin GITS and Atenolol
Number of subjects: 60
Study: 16134134

Group type: EXPERIMENTAL
Intervention: Limited (D1) lymph node dissection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Extended (D2) lymph node dissection
Number of subjects: 0
Study: 12075268

Group type: EXPERIMENTAL
Intervention: Nutritional supplementation with carnitine, CoQ10, and taurine
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Nutritional supplementation
Number of subjects: 41
Study: 10633314

Group type: EXPERIMENTAL
Intervention: Women with borderline personality disorder (BPD)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Women with histories of childhood sexual abuse (no BPD)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Women with no history of sexual abuse or BPD
Number of subjects: 62
Study: 8546658

Group type: EXPERIMENTAL
Intervention: Mifepristone combined with gemeprost (prostaglandin analogue)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Mifepristone alone
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Mifepristone combined with gemeprost
Number of subjects: 20
Study: 1958475

Group type: EXPERIMENTAL
Intervention: Busulphan and thioguanine
Number of subjects: 675

Group type: COMPARATOR
Intervention: Busulphan alone
Number of subjects: 675
Study: 31466022

Group type: COMPARATOR
Intervention: DBS leads inserted using conventional landmarks (Group A)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Leads guided into the DRTT using DTIT (Group B)
Number of subjects: 34
Study: 30409962

Group type: EXPERIMENTAL
Intervention: XPD siRNA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: P53 inhibitor (1 μM bpV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Negative Control (NC)
Number of subjects: 0
Study: 25987674

Group type: EXPERIMENTAL
Intervention: Parent-child interactive intervention
Number of subjects: 75

Group type: COMPARATOR
Intervention: Written materials on tobacco hazards (Control)
Number of subjects: 75
Study: 24556289

Group type: EXPERIMENTAL
Intervention: Complex intervention for the management of osteoarthritis
Number of subjects: 14
Study: 22351883

Group type: EXPERIMENTAL
Intervention: SafeCare (SC) model for child neglect
Number of subjects: 2175

Group type: COMPARATOR
Intervention: Comparable home-based services without SC modules (Control)
Number of subjects: 2175
Study: 20028464

Group type: EXPERIMENTAL
Intervention: Placebo treatment (sham acupuncture)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-treatment group (waitlist)
Number of subjects: 0
Study: 18556085

Group type: EXPERIMENTAL
Intervention: Modified Yale insulin infusion protocol (MY group)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Empirical blood glucose control (EC group)
Number of subjects: 75
Study: 15821487

Group type: EXPERIMENTAL
Intervention: GnRH agonists (GnRH-A)
Number of subjects: 80
Study: 12356612

Group type: EXPERIMENTAL
Intervention: Chiropractic care
Number of subjects: 672

Group type: COMPARATOR
Intervention: Medical care
Number of subjects: 672
Study: 10487267

Group type: EXPERIMENTAL
Intervention: Cilostazol 100 mg orally twice daily
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Pentoxifylline 400 mg orally three times daily
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 9081556

Group type: EXPERIMENTAL
Intervention: Conditioned stimulus plus 10 mg of cyclophosphamide
Number of subjects: 10

Group type: COMPARATOR
Intervention: Cyclophosphamide (unconditioned stimulus)
Number of subjects: 10
Study: 1936485

Group type: EXPERIMENTAL
Intervention: Metformin (2 tabs/d, i.e. 1,700 mg/d)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo (2 tabs/d)
Number of subjects: 400
Study: 6217028

Group type: EXPERIMENTAL
Intervention: Triphasic oral contraceptive (30-40-30 micrograms EE and 50-75-125 micrograms levonorgestrel)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Fixed dose oral contraceptive (30 micrograms EE and 150 micrograms desogestrel)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Triphasic oral contraceptive
Number of subjects: 193

Group type: COMPARATOR
Intervention: Fixed dose oral contraceptive
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Both preparations
Number of subjects: 193
Study: 31552500

Group type: EXPERIMENTAL
Intervention: Whole grain oats cooked under normal pressure (WONP)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Whole grain oats cooked under higher pressure (WOHP)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Pearled oats cooked under normal pressure (PONP)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Pearled oats cooked under higher pressure (POHP)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Oat-rice mixed meals (OG + R) including WONP + R, WOHP + R, PONP + R, POHP + R
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: WONP + R
Number of subjects: 10

Group type: COMPARATOR
Intervention: Oat-rice mixed meals (OG + R)
Number of subjects: 10
Study: 30897865

Group type: EXPERIMENTAL
Intervention: TEAS nursing group
Number of subjects: 100
Study: 27052428

Group type: EXPERIMENTAL
Intervention: Albuvirtide (320 mg) and Lopinavir/Ritonavir (400/100 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Lopinavir/Ritonavir (400/100 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Ritonavir
Number of subjects: 10
Study: 26293147

Group type: EXPERIMENTAL
Intervention: Supervised aerobic and resistance exercise (n = 44)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Usual care (n = 45)
Number of subjects: 94
Study: 23855176

Group type: EXPERIMENTAL
Intervention: Oral Midazolam 0.5 mg/kg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Oral Diazepam 0.5 mg/kg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Intravenous Midazolam 0.06 mg/kg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Oral Placebo
Number of subjects: 40
Study: 21394570

Group type: EXPERIMENTAL
Intervention: Pharmacotherapy follow-up (PF)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 161
Study: 19643769

Group type: EXPERIMENTAL
Intervention: Effective CPAP
Number of subjects: 56

Group type: COMPARATOR
Intervention: Sham CPAP
Number of subjects: 56
Study: 17950834

Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stent (ZES)
Number of subjects: 1306
Study: 15889589

Group type: EXPERIMENTAL
Intervention: Circumferential static wrist orthoses (custom-fit)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Circumferential static wrist orthoses (off-the-shelf)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no wrist orthoses)
Number of subjects: 30
Study: 12520634

Group type: EXPERIMENTAL
Intervention: Capecitabine (1,000 mg/m2 twice daily on days 1 to 14) plus IV irinotecan (250 mg/m2 on day 1 every 21 days)
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Capecitabine/irinotecan
Number of subjects: 700

Group type: COMPARATOR
Intervention: 5‐FU/leucovorin
Number of subjects: 700
Study: 9695724

Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 31
Study: 7521118

Group type: COMPARATOR
Intervention: Chlormadinone acetate alone (group A)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Chlormadinone acetate in combination with UFT (group B)
Number of subjects: 70
Study: 2683878

Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Aziatropine
Number of subjects: 36
Study: 4524016

Group type: EXPERIMENTAL
Intervention: Topical fluoride application once a year
Number of subjects: 487

Group type: EXPERIMENTAL
Intervention: Topical fluoride application twice a year with 6 month interval
Number of subjects: 487

Group type: COMPARATOR
Intervention: No topical fluoride application (control group)
Number of subjects: 487
Study: 30388270

Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 68

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 68
Study: 28034081

Group type: EXPERIMENTAL
Intervention: Ipilimumab 10 mg/kg
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study: 25110841

Group type: EXPERIMENTAL
Intervention: HIV/STI risk‐reduction intervention
Number of subjects: 9

Group type: COMPARATOR
Intervention: Attention-control intervention
Number of subjects: 9
Study: 23594263

Group type: EXPERIMENTAL
Intervention: Recombinant human C1 inhibitor (rhC1INH) administered at a dosing scheme of 50 U kg(‐1) up to 84 kg, with a fixed dose of 4200 U above 84 kg.
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Recombinant human C1 inhibitor (rhC1INH) in symptomatic HAE patients.
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Recombinant human C1 inhibitor (rhC1INH) in healthy volunteers.
Number of subjects: 133
Study: 21615875

Group type: COMPARATOR
Intervention: Conventional dose CTPI (19.62 mSv)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Median dose CTPI (12.61 mSv)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Low-dose CTPI (7.01 mSv)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Low-dose CTPI in patients with HCC
Number of subjects: 47
Study: 19492636

Group type: EXPERIMENTAL
Intervention: Cone-beam imaging (CB)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Orthopantomography (OPG)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Computerized Tomography (CT)
Number of subjects: 27
Study: 17109592

Group type: EXPERIMENTAL
Intervention: Twice-daily NPH/regular insulin
Number of subjects: 94

Group type: COMPARATOR
Intervention: Once-daily glargine insulin
Number of subjects: 94
Study: 15379419

Group type: EXPERIMENTAL
Intervention: Infants of mothers with gestational diabetes mellitus (IGDM)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: All study participants
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Infants with postnatal hypoglycemia
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Maternal HbA1c during pregnancy
Number of subjects: 37
Study: 11483801

Group type: EXPERIMENTAL
Intervention: AA+DHA from fish/fungal oil (N = 140)
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: AA+DHA from egg‐TG/fish oil (N = 143)
Number of subjects: 470

Group type: COMPARATOR
Intervention: Control (N = 144)
Number of subjects: 470
Study: 9462387

Group type: COMPARATOR
Intervention: MMP-9 level at 24 hours after operation
Number of subjects: 15

Group type: COMPARATOR
Intervention: MMP-2 and MMP-9 levels in wound fluid
Number of subjects: 15

Group type: COMPARATOR
Intervention: MMP-9 level at 24-48 hours after operation
Number of subjects: 15
Study: 7520297

Group type: EXPERIMENTAL
Intervention: Hypertonic saline solution with low molecular weight hydroxyethyl starch (HS-HES)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Low molecular weight hydroxyethyl starch solution (LMW-HES)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (no volume loading)
Number of subjects: 45
Study: 2837106

Group type: EXPERIMENTAL
Intervention: terbutaline (7 micrograms/kg, subcutaneous injection)
Number of subjects: 18

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study: 29297230

Group type: EXPERIMENTAL
Intervention: Vacc-4x
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study: 27466000

Group type: EXPERIMENTAL
Intervention: Custom-made foot orthoses (CMFOs)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Simple insoles (SIs)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness comparison
Number of subjects: 41
Study: 26550795

Group type: EXPERIMENTAL
Intervention: Continuous chest compressions
Number of subjects: 23711

Group type: COMPARATOR
Intervention: Interrupted chest compressions
Number of subjects: 23711
Study: 22585541

Group type: EXPERIMENTAL
Intervention: loose snus (27.1 mg nicotine)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: pouched snus (14.7 mg nicotine)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: loose snus (10.8 mg nicotine)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: nicotine gum (4.2 mg nicotine)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: cigarette
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: pouched snus (1 g portion, ~11 mg nicotine)
Number of subjects: 20
Study: 21577030

Group type: EXPERIMENTAL
Intervention: 10-week twice weekly exercise group program (gymnastics, movement games, relaxation, walking, jogging)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Waiting group (control)
Number of subjects: 58
Study: 18283240

Group type: EXPERIMENTAL
Intervention: Increased serum concentrations of IgM and IgA against LPS from gram-negative enterobacteria in MDD patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diagnostic performance of IgM and IgA levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Symptoms associated with increased IgM and IgA levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intestinal mucosal dysfunction (leaky gut)
Number of subjects: 0
Study: 16765863

Group type: EXPERIMENTAL
Intervention: Clinical pathway for treating pneumonia
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Nursing administrators' perspective
Number of subjects: 6
Study: 12668300

Group type: EXPERIMENTAL
Intervention: Feedback group
Number of subjects: 36
Study: 10505800

Group type: EXPERIMENTAL
Intervention: Systemic bone mineral density (BMD) measures
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Generalized osteopenia
Number of subjects: 292
Study: 8904260

Group type: EXPERIMENTAL
Intervention: Combination of diazepam and propofol
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Diazepam alone
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Propofol alone
Number of subjects: 150
Study: 2276106

Group type: EXPERIMENTAL
Intervention: Weekly telephone call intervention in addition to usual care
Number of subjects: 55

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 55
Study: 533286

Group type: EXPERIMENTAL
Intervention: Combined topical applications of a steroid and nonsteroid anti-inflammatory agent
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonsteroid anti-inflammatory agent
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of steroid and nonsteroid agents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Steroid or nonsteroid agent alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of agents
Number of subjects: 0
Study: 30022296

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study: 28877245

Group type: EXPERIMENTAL
Intervention: Engaging unpaid informal providers (IPs) in the Early arm
Number of subjects: 410278

Group type: COMPARATOR
Intervention: Delayed arm (control)
Number of subjects: 410278
Study: 25766689

Group type: EXPERIMENTAL
Intervention: Primary Care (PC)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Sleep Unit (SU)
Number of subjects: 210
Study: 25139550

Group type: COMPARATOR
Intervention: gemcitabine/cisplatin (GC)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: gemcitabine/cisplatin/iniparib (GCI)
Number of subjects: 119
Study: 22459230

Group type: EXPERIMENTAL
Intervention: Parenteral hydration
Number of subjects: 85
Study: 19088698

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion (0.25 microg kg(‐1) hr(‐1))
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Midazolam infusion (25 microg kg(‐1) hr(‐1))
Number of subjects: 90

Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 90
Study: 17604045

Group type: EXPERIMENTAL
Intervention: Early invasive treatment strategy
Number of subjects: 1163

Group type: COMPARATOR
Intervention: Selective invasive (SI) treatment strategy
Number of subjects: 1163

Group type: COMPARATOR
Intervention: Patients with SigmaST-segment deviation of at least 1 mm randomized to SI who did not undergo angiography
Number of subjects: 1163

Group type: EXPERIMENTAL
Intervention: Patients with SigmaST-segment deviation of at least 1 mm who underwent angiography before discharge
Number of subjects: 1163

Group type: EXPERIMENTAL
Intervention: Presence of ST-segment deviation
Number of subjects: 1163
Study: 15998467

Group type: EXPERIMENTAL
Intervention: Epidural blood patch (EDBP)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional treatment (24 hours bed rest and ample fluid intake)
Number of subjects: 40
Study: 11929349

Group type: EXPERIMENTAL
Intervention: Triflusal (600 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin (300 mg/day)
Number of subjects: 0
Study: 9468157

Group type: EXPERIMENTAL
Intervention: Minocycline and rifampin-coated catheters
Number of subjects: 158

Group type: COMPARATOR
Intervention: Uncoated catheters (control)
Number of subjects: 158
Study: 7630912

Group type: EXPERIMENTAL
Intervention: Oral care regime using saline rinses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral assessment guide and protocol
Number of subjects: 0
Study: 2905069

Group type: EXPERIMENTAL
Intervention: Acetazolamide (500 mg daily)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Temazepam (10 mg for one night)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo (for one night)
Number of subjects: 6
Study: 28278611

Group type: EXPERIMENTAL
Intervention: Allow Natural Death (AND)
Number of subjects: 234

Group type: COMPARATOR
Intervention: Do Not Resuscitate (DNR)
Number of subjects: 234
Study: 28247979

Group type: COMPARATOR
Intervention: High-intensity aerobic training (HAT, 75% HRR)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Moderate-intensity aerobic training (MAT, 60% HRR)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Control group (CG)
Number of subjects: 34
Study: 26243144

Group type: EXPERIMENTAL
Intervention: Tailored feedback
Number of subjects: 87

Group type: COMPARATOR
Intervention: Generic feedback
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Both tailored and generic feedback
Number of subjects: 87
Study: 23714894

Group type: EXPERIMENTAL
Intervention: Poly(lactic-co-glycolic) acid/hydroxyapatite (PLGA/HA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Deproteinized bovine bone (DBB)
Number of subjects: 0
Study: 20386078

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF) 300 mg once daily for 2 weeks
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo for 2 weeks
Number of subjects: 19
Study: 18377693

Group type: EXPERIMENTAL
Intervention: Co-enzyme Q10 (100 mg), Riboflavin (10 mg), Niacin (50 mg) along with Tamoxifen (10 mg twice per day)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Tamoxifen alone
Number of subjects: 84

Group type: COMPARATOR
Intervention: Untreated breast cancer patients
Number of subjects: 84
Study: 20356911

Group type: EXPERIMENTAL
Intervention: Intravenous n-3 polyunsaturated fatty acids (PUFA) infusion (3.9 g)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Intravenous n-3 PUFA infusion
Number of subjects: 8
Study: 15598604

Group type: EXPERIMENTAL
Intervention: Stress situation
Number of subjects: 153

Group type: COMPARATOR
Intervention: No-stress situation
Number of subjects: 153
Study: 11403364

Group type: EXPERIMENTAL
Intervention: Amlodipine (5/10 mg) +/‐ Perindopril (4/8 mg)
Number of subjects: 19342

Group type: COMPARATOR
Intervention: Atenolol (50/100 mg) +/‐ Bendroflumethiazide (1.25/2.5 mg) + K+
Number of subjects: 19342

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg
Number of subjects: 19342

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19342
Study: 9755995

Group type: EXPERIMENTAL
Intervention: Lansoprazole 15 mg at bedtime (maintenance group)
Number of subjects: 84

Group type: COMPARATOR
Intervention: No active therapy (antibiotic group)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Lansoprazole 15 mg at bedtime (intent to treat analysis)
Number of subjects: 84

Group type: COMPARATOR
Intervention: No active therapy (intent to treat analysis)
Number of subjects: 84